Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis

NCT ID: NCT04120675

Last Updated: 2021-07-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-09
• Study Completion Date: 2021-06-06

Brief Summary

To date, no drug therapy has been approved for primary (PPMS) & secondary (SPMS) progressive multiple sclerosis. The urgent need to find new therapies - if possible with minimal side effects - led us to the search for the potential therapeutic effects of early harvest olive oil. The positive effect of phenol-rich, flavonoid and lignin-based olive oil on the modification of intestinal microbe populations and their by-products of metabolism is well known, such as the extent of gut-associated lymphoid tissue immune-stimulation due to antioxidants, anti-inflammatory and immunoregulatory properties. The aim of this Greek, Randomized Clinical Trial, is to evaluate the effect of Early Harvest Extra Virgin Olive Oil on cognition and mental health of patients diagnosed with PPMS or SPMS. The patients will be evaluated once at the beginning of treatment, after 6 months of treatment and after twelve months of treatment, in order to specify the eficacy of extra virgin olive oil in holistic treatments for SPMS and PPMS

Detailed Description

Study Type: Randomized Clinical Trial. Primary Purpose: Prevention OBJECTIVES OF THE TRIAL The objectives of this study are:To investigate the efficacy of Early Harvest EVOO as a disease course modifying treatment for primary (PPMS) or secondary (SPMS) progressive multiple sclerosis in a phase III randomized controlled clinical trial study in objective measurements in patients with primary (PPMS) or secondary (SPMS) progressive multiple sclerosis.

STUDY DESIGN This is a Greek, randomized controlled study group of Early Harvest EVOO to a control group, in which the patients will receive only their symptomatic medication. Qualifying patients will be randomly assigned to receive 50mL of Early Harvest EVOO or not on a daily basis for 24 months. Patients undergo assessments at baseline, 6 and 12 months +/- 7 days after beginning treatment.

Duration: The total study duration will be 12 months. Patients will receive study interventions for 12 months.

Number of Subjects 30 subjects total will be enrolled; 20 in the experimental group (Early Harvest EVOO); 10 in the Control group

Conditions

Progressive Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Experimental group

Experimental Group 20 patients on Early Harvest Extra Virgin Olive Oil Aluminum bottle with 500 ml of early harvest extra virgin olive oil (3 tablespoons per day).

Dietary Supplement: Early Harvest Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)

Group Type: EXPERIMENTAL

Early Harvest Extra Virgin Olive Oil

Intervention Type: DIETARY_SUPPLEMENT

Participants will take 3 tablespoons on a daily basis

Control group

10 patients will not receive treatment with Extra Virgin Olive Oil

Group Type: ACTIVE_COMPARATOR

Early Harvest Extra Virgin Olive Oil

Intervention Type: DIETARY_SUPPLEMENT

Participants will take 3 tablespoons on a daily basis

Interventions

Early Harvest Extra Virgin Olive Oil

Participants will take 3 tablespoons on a daily basis

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Confirmed diagnosis of primary (PPMS) or secondary (SPMS) progressive multiple sclerosis
• EDSS≥ 5
• No response to any given treatment for MS or interruption due to side effects
• Progressive aggravation in the disease's progression estimated by: deterioration in EDSS-plus disability scale, Timed 25-Foot Walk or 9-hole peg test.
• Progressive aggravation in the disease's progression estimated by: new lesions in MRI scan and neuropsychological tests
• Progressive aggravation in patient's neuropsychological status
• Progressive aggravation in patient's Quality of life, estimated with MuSIQol - Greek 3.01 MS and SF-36
• Years of education: >= 5
• Proficient language fluency
• Have a study partner with 10+ hr/wk contact (can be in person and telephone), accompanies to visits
• Compliance

Exclusion Criteria

• Enrollment in other trials or studies not compatible with MSOIL
• Visual and auditory acuity inadequate for neuropsychological testing
• History of significant other neurological or psychiatric illnesses or presence of other diseases precluding enrollment.
• Use of forbidden medications (listed below)
• Ferromagnetic implants and devices (including implants or devices held in place by sutures, granulation or ingrowth of tissue, fixation devices, or by other means) not eligible for MRI scanning. Brain malformation or other conditions that may complicate lumbar puncture
• Any significant or uncontrolled medical condition or treatment-emergent
• Clinically significant laboratory abnormality

Medications across the study

Excluded Medication:

• Immunosuppressant or immunomodulating agents, corticosteroids, or investigational drugs within 3 months of study initiation
• Antibiotics in general, at least one month prior assessment of specific inflammatory markers (faecal levels of calprotectin, metabolomic profile, gut microbiota)
• Use of neuroleptics or within 4 weeks of screening
• Participation in any other investigational drug study within 4 weeks of screening (individuals may not participate in any drug study while participating in this protocol).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Greek Alzheimer's Association and Related Disorders

OTHER

Sponsor Role: collaborator

Ellis-Farm, Eliama Daily Value Gold (ellis-farm.com)

UNKNOWN

Sponsor Role: collaborator

Aristotle University Of Thessaloniki

OTHER

Sponsor Role: lead

Responsible Party

Magda Tsolaki

MD, PhD, Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

A' Department of Neurology,Aristotle University of Thessaloniki (AUTH)

Thessaloniki, Macedonia, Greece

Countries

Greece

Other Identifiers

43-Α/24-10-2018

Identifier Type: -

Identifier Source: org_study_id